A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
PublisherLippincott Williams and Wilkins
MetadataShow full item record
AbstractConsiderable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era.MethodsWe carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence.ResultsWe developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment.ConclusionsBy addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist. Copyright 2019 American Academy of Neurology.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062387063&doi=10.1212%2fWNL.0000000000007044&partnerID=40&md5=d958e3e2895acab63fc8a98870e3427e; http://hdl.handle.net/10713/10535
- Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.
- Authors: Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, Muravov O, Horton K
- Issue date: 2016 Aug 5
- The prevalence of MS in the United States: A population-based estimate using health claims data.
- Authors: Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup.
- Issue date: 2019 Mar 5
- Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.
- Authors: Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Muravov O, Horton K, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia., Centers for Disease Control and Prevention (CDC).
- Issue date: 2014 Jul 25
- Multiple sclerosis prevalence in the United States commercially insured population.
- Authors: Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD
- Issue date: 2016 Mar 15
- Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care Programs.
- Authors: Livingston T, Fay M, Iyer R, Wells W, Pill MW
- Issue date: 2016 Dec